🕵️ Faeth Therapeutics, Inc. ($FTH)
SEC insider & ownership activity, last 12 months · CIK 1829802 · every row links its SEC filing
Over the last 12 months insiders sold $2.3M against $2.5M of open-market buying. Millennium Management LLC bought $1.3M (Mar–Apr). No red-flag 8-Ks in the window.
🚨 1 signal active —
planned-vs-executed verdicts, pre-event flags, and cluster context live in the
API and the
alerts bot.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
3 buyers, $2.5M (49 lots) · 3 sellers, $2.3M (45 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Millennium Management LLC | 26 | $1.3M | 25 | $704K | Apr 7, 2026 |
| Brian C. Stephenson | 22 | $1.1M | 0 | – | Jul 1, 2026 |
| Cambrian Biopharma Inc | 0 | – | 10 | $788K | Jun 1, 2026 |
| Peyer James | 0 | – | 10 | $788K | Jun 1, 2026 |
| Parikh Anand Kiran | 1 | $55K | 0 | – | Jun 22, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| S2G Investments, LLC | 10.0% | 13G | Jun 23, 2026 | filing ↗ | |
| Trails EDGE Capital Partners, LP | 9.9% | 13G | Feb 25, 2026 | filing ↗ | |
| Trails EDGE Biotechnology Master Fund, LP | 9.9% | 13G | Feb 25, 2026 | filing ↗ | |
| Ortav Yehudai | 9.9% | 13G | Feb 25, 2026 | filing ↗ | |
| Stempoint Capital LP | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Stempoint Capital Management GP LLC | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Michelle Ross | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Caligan Partners LP | 9.4% | 13G | May 15, 2026 | filing ↗ | |
| David Johnson | 9.4% | 13G | May 15, 2026 | filing ↗ | |
| Suvretta Capital Management, LLC | 7.8% | 13G | Jun 23, 2026 | filing ↗ | |
| Aaron Cowen | 7.8% | 13G | Jun 23, 2026 | filing ↗ | |
| Averill Master Fund, Ltd. | 6.7% | 13G | Jun 23, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Cambrian Biopharma Inc | $5.0M | Apr 29, 2026 | filing ↗ |
| Celebi John | $116K | Feb 24, 2026 | filing ↗ |
| Peyer James | $26K | Feb 18, 2026 | filing ↗ |
| William R. Ringo | $11K | Jan 27, 2026 | filing ↗ |
| Peyer James | $7K | Dec 9, 2025 | filing ↗ |
| Cambrian Biopharma Inc | $51K | Dec 4, 2025 | filing ↗ |
| Cambrian Biopharma Inc | $185K | Dec 4, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Officer/director changes (5.02) | Jul 21, 2026 | filing ↗ |
| Material agreement (1.01) | Jun 15, 2026 | filing ↗ |
| Other events (8.01) | Jun 15, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 15, 2026 | filing ↗ |
| Agreement terminated (1.02) | Jun 10, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 10, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Jun 10, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 10, 2026 | filing ↗ |
| Other events (8.01) | Jun 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 10, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 10, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Jun 10, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 10, 2026 | filing ↗ |
| Other events (8.01) | May 22, 2026 | filing ↗ |
| Other events (8.01) | May 21, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 21, 2026 | filing ↗ |
| Earnings (2.02) | May 15, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 15, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 10, 2026 | filing ↗ |
| Earnings (2.02) | Mar 30, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 30, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 17, 2026 | filing ↗ |
| Material agreement (1.01) | Feb 17, 2026 | filing ↗ |
| Acquisition or disposition (2.01) | Feb 17, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Feb 17, 2026 | filing ↗ |
| Officer/director changes (5.02) | Feb 17, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Feb 17, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 17, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 17, 2026 | filing ↗ |